ReviewActa pharmaceutica Sinica. B2026
Nanomaterial-mediated functional remodeling of antigen-presenting cells: A novel strategy to break tumor immune escape.
Review in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the cross-integration of nanotechnology and immunology, nanomaterials have shown great potential in tumor treatment. This review begins with the nanomaterials have unique advantages in reshaping the tumor immune microenvironment (TIME), including improving targeting, enhancing stability, increasing delivery efficiency, achieving controllable release, and endowing a multi-functional integrated platform. We then systematically reviews the recently research progress on the multi-mechanism regulation of antigen-presenting cells (APCs) by nanomaterials: (1) In the aspect of dendritic cell activation, we focus on the breakthrough achievements such as the activation of immune responses through the generation of immune signal complexes and the promotion of tumor neoantigen presentation; (2) In the field of macrophage reprogramming, we analyze the applications of nanomaterials in inducing macrophage polarization, improving the anti-tumor phagocytosis of macrophages, blocking macrophage autophagy, and enhancing the synergy of immune cells; (3) In the regulation of B cells, we explore the mechanism by which nanomaterials enhance the germinal center response and thereby exert anti-tumor immune effects. This article further discusses key challenges in clinical translation, including the dynamic fate of nanomaterials in complex TIME and the balance between immunogenicity and efficacy, and proposes future directions for accelerating clinical translation through computer-aided design (such as AI prediction of nanomaterial-immune cell interaction networks) and organ-on-a-chip evaluation systems. This review provides a theoretical framework and technical route for the development of next-generation tumor immunonanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.